Skip to main content

Advertisement

Table 2 Summary of rFVIIa treated other bleeding patients (OBP) who survived >4 hours

From: Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage

P# Age Sex Procedure Co-morbidities Response to rFVIIa Outcome
     Pre rFVIIa Post rFVIIa  
     R P F C R P F C  
2* 48F Colectomy Colon cancer 4 6 24 70 2 0 2 0 Died
15* 26F Cystectomy, nephrectomy, pelvic fracture, termination of Pregnancy MVA, 20 weeks gestation 18 12 8 0 6 6 10 0 Survived
16 53M Left femur fixation Multiple myeloma 12 12 6 0 0 0 0 0 Survived
19 82M Shoulder replacement HTN, CAD, Renal failure 7 10 20 10 2 6 4 0 Survived
21 54F Liver laceration Trauma 23 17 34 20 3 6 10 0 Survived
22 24M Neck soft tissue trauma FVII deficiency 2 0 4 0 0 0 0 0 Survived
23 64F Liver laceration Dialysis 28 36 33 0 0 0 0 0 Died
28 30F Postpartum hemorrhage None 12 18 6 10 0 0 0 0 Survived
29 64M Gastrointestinal bleed FVIII inhibitor 2 0 0 0 0 0 0 0 Survived
38 60M Thyroidectomy VWF deficiency 4 12 12 4 0 0 0 0 Survived
40 40F Splenic subcapsular bleed Amyloidosis, coumadin overdose 4 0 8 0 0 0 0 0 Survived
Average     10 11 14 10 1 2 2 0  
P value         .004 .017 .017 .122  
  1. P: Patient
  2. R: Red Blood Cell;
  3. P: Platelet; F: Fresh Frozen Plasma; C: Cryoprecipitate
  4. M: Male; F: Female
  5. EF: Left Ventricular Ejection Fraction
  6. VWF: von Willebrand Factor
  7. * Patient continued to require blood transfusion past 24 hours post rFVIIa treatment.